You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: Radiant Creative Group, LLC Topic: NICHD
ABSTRACT The goal of thisyear Fast Track STTR is to develop and evaluate a multi levelyouthparentschoolInternet based dating violenceDVprevention programMe andampYou TechMYTforthgrade middle school studentsByth gradeapproximatelyof students will have engaged in a dating relationshipOf thesealmost one third will have perpetrated physical DV and almost two thirds will have perpetrated emotional DVYo ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: TED'S BRAIN SCIENCE INCORPORATED Topic: N
More thanindividuals undergo laser vision correction surgery each year in the United Statesincluding laser assisted in situ keratomileusisLASIKand photorefractive keratectomyPRKThese procedures damage the nerves in the corneal epithelium causing intense acute pain that most patients rate as greater thanon ascalemany report the pain to beunbearableeven after analgesic treatmentWhile virtually all p ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
A high-efficiency, low-cost, single-use purification technology for therapeutic antibody manufacturingSBC: Bondwell Technologies Inc. Topic: 400
Therapeutic antibodies have had a profound impact on treatment of many types of cancer and autoimmune diseasesAs a resultfive of the top ten best selling drugs ofwere therapeutic antibodiesMore than seventy therapeutic antibodies have been approvedand over six hundred antibody based products are in clinical developmentHoweverantibodies are extremely expensive to produceand large amounts of antibod ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
Preclinical studies to validate the efficacy of novel mechanism-of-action small molecule inhibitors to treat Duchenne muscular dystrophySBC: RIDGELINE THERAPEUTICS LLC Topic: NIAMS
Progressive muscle weakness and degeneration is a hallmark of Duchenne muscular dystrophyDMDIn DMD patientsthe lack of dystrophin reduces muscle fiber structural integritymaking muscles vulnerable to persistent injury and damageRepairing these damaged muscles requires the continual activation of muscle stem cellsmuSCwhich leads to muSC dysfunction and senescenceand ultimately the muscle degenerati ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: Data2Care Technologies, LLC Topic: NICHD
Project Summary Abstract Acute gastroenteritisAGEinfectious diarrhea is a common condition that is costly in the US and highmortality in developing nationsThe cornerstone of AGE management is oral rehydration therapyORTan evidence based technique that has saved overmillion lives in theyears since its introductionThe problem we aim to address is ORT s underuse in developed countries specifically in ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: Lacerta Therapeutics, Inc. Topic: 102
Glioblastoma (GBM) is the most lethal form of adult brain cancers with a median survival of andlt;15 months despite aggressive standard chemoradiation. GBM are formed by GBM stem-like cells (GSCs) - a major contributor to tumor recurrence and a natural focus for therapeutic development. There are two main reasons responsible for treatment failure: 1) high intra- and inter-tumor cellular and molecu ...STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
A Randomized, Blinded, Placebo-Controlled Clinical Trial to Evaluate Longeveron Mesenchymal Stem Cell (LMSC) Therapy for Treating The Metabolic SyndromeSBC: Longeveron LLC Topic: NIA
The metabolic syndrome (MetS) is a cluster of factors that increases the risks for cardiovascular disease, type 2 diabetes mellitus, and mortality, and currently affects andgt; 40% of US adults. MetS is associated with endothelial dysfunction, decreased circulating endothelial progenitor cells (EPCs), and a pro-inflammatory state. We have made the exciting discovery that therapy with allogeneic me ...STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: GalaxyWorks LLC Topic: NHGRI
Project Summary Galactic Core LLC aims to develop a robust, scalable, and managed service for performing enterprise-grade biomedical data analysis. The service will be based on the popular open-source Galaxy application (https://galaxyproject.org/), offering unlimited data storage and compute capabilities with an extremely powerful, flexible, and collaborative environment for analyzing data. ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
SBC: CLEARNANO INC Topic: 400
SummarySystemic lupus erythematosusSLEor lupus is an autoimmune disease that impacts more thanmillion people worldwideincludingmillion AmericansNearlyof these patients will develop lupus nephritiswhich can cause kidney failureAs a resultits financial burden to individual patient can reach $yearmuch higher than many other diseases because of kidney transplantationAlthough early treatment of lupus n ...STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
Highly selective detection of tau oligomers in biological fluids for the diagnosis of Alzheimer's DiseaseSBC: Amprion, Inc. Topic: NIA
This proposal is for a phase I/II fast track project for the STTR program with the main goal to develop a test for high sensitive detection of tau oligomers in biological fluids, which could be used for the biochemical diagnosis of Alzheimer’s disease (AD) and related tauopathies. AD is the most common dementia in the elderly population and one of the leading causes of death in the developed wor ...STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health